These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22198693)

  • 41. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 45. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Worsening of subacute lupus erythematosus induced by infliximab].
    Vabre-Latre CM; Bayle P; Marguery MC; Gadroy A; Durand D; Bazex J
    Ann Dermatol Venereol; 2005 Apr; 132(4):349-53. PubMed ID: 15886563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 48. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.
    Yokoyama W; Takada K; Miyasaka N; Kohsaka H
    BMJ Case Rep; 2014 Aug; 2014():bcr-2014-205779. PubMed ID: 25085953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical experience with TNF-blockers].
    Forster A; Michel BA
    Z Rheumatol; 2001 Oct; 60(5):319-25. PubMed ID: 11759231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P; Crnkic M; Petersson IF; Saxne T;
    Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intestinal necrosis in a patient with rheumatoid arthritis receiving anti-TNF treatment.
    Ruppert M; De Clerck L; van Offel J; Hubens G; Balliu L; Vaneerdeweg W
    Acta Chir Belg; 2006; 106(2):225-7. PubMed ID: 16761484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cryptococcal meningitis in a patient treated with infliximab.
    Muñoz P; Giannella M; Valerio M; Soria T; Díaz F; Longo JL; Bouza E
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):443-6. PubMed ID: 17240111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 57. Infliximab-induced discoid lupus erythematosus.
    Cemil BC; Atas H; Canpolat F; Akca Y; Sasmaz R
    Lupus; 2013 Apr; 22(5):515-8. PubMed ID: 23554040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].
    Imagama T; Taguchi T
    Nihon Rinsho; 2013 Jul; 71(7):1209-13. PubMed ID: 23961668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.